Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials.

Willer DO, Oostvogels L, Cunningham AL, Gervais P, Gorfinkel I, Hyung Kim J, Talarico C, Wascotte V, Zahaf T, Colindres R, Schuind A; ZOE 50/70 study groups.

Vaccine. 2019 Oct 8;37(43):6262-6267. doi: 10.1016/j.vaccine.2019.09.028. Epub 2019 Sep 16.

2.

2018 European guideline on the organization of a consultation for sexually transmitted infections.

Gamoudi D, Flew S, Cusini M, Benardon S, Poder A, Radcliffe K.

J Eur Acad Dermatol Venereol. 2019 Aug;33(8):1452-1458. doi: 10.1111/jdv.15577. Epub 2019 Apr 10. No abstract available.

PMID:
30968975
3.

Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.

López-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, Diez-Domingo J, Heineman TC, Lal H, McElhaney JE, McNeil SA, Yeo W, Tavares-Da-Silva F; ZOE-50/70 Study Group.

Vaccine. 2019 Apr 24;37(18):2482-2493. doi: 10.1016/j.vaccine.2019.03.043. Epub 2019 Mar 29.

4.

Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial' [Vaccine 36 (2018) 4278-4286].

Maréchal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman TC, Hervé C, Rheault P, Talli J, Wauters D, Oostvogels L.

Vaccine. 2019 Feb 21;37(9):1252-1253. doi: 10.1016/j.vaccine.2019.01.022. Epub 2019 Jan 30. No abstract available.

5.

The growing and important collaboration between BASHH and IUSTI-Europe.

Patel R, Sherrard J, Richardson D, Poder A.

Sex Transm Infect. 2018 Nov;94(7):474. doi: 10.1136/sextrans-2018-053744. Epub 2018 Jul 17. No abstract available.

PMID:
30018087
6.

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.

Maréchal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman TC, Hervé C, Rheault P, Talli J, Wauters D, Oostvogels L.

Vaccine. 2018 Jul 5;36(29):4278-4286. doi: 10.1016/j.vaccine.2018.05.110. Epub 2018 Jun 11. Erratum in: Vaccine. 2019 Feb 21;37(9):1252-1253.

7.

MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16/18 in girls and young women: Results from a phase III randomized trial.

Rivera L, Chanthavanich P, Põder A, Suryakiran PV, Jastorff A, Van der Wielen M.

Vaccine. 2018 Jun 22;36(27):3967-3975. doi: 10.1016/j.vaccine.2018.05.051. Epub 2018 May 19.

8.

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).

Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, Gómez-Reino JJ, Aelion JA; ACTIVE investigators.

Ann Rheum Dis. 2018 May;77(5):690-698. doi: 10.1136/annrheumdis-2017-211568. Epub 2018 Jan 17.

9.

Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.

Lal H, Poder A, Campora L, Geeraerts B, Oostvogels L, Vanden Abeele C, Heineman TC.

Vaccine. 2018 Jan 2;36(1):148-154. doi: 10.1016/j.vaccine.2017.11.019. Epub 2017 Nov 22.

10.

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators.

N Engl J Med. 2016 Dec 15;375(24):2335-2348. Epub 2016 Sep 30.

11.

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group.

N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800.

12.

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.

Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz-González F, Van den Bosch F, Marzo-Ortega H, Feist E, Shah K, Hu C, Stevens RM, Poder A.

J Rheumatol. 2016 Sep;43(9):1724-34. doi: 10.3899/jrheum.151376. Epub 2016 Jul 15.

PMID:
27422893
13.

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC; ZOE-50 Study Group.

N Engl J Med. 2015 May 28;372(22):2087-96. doi: 10.1056/NEJMoa1501184. Epub 2015 Apr 28.

14.

Effect of glucose content on thermally cross-linked fibrous gelatin scaffolds for tissue engineering.

Siimon K, Reemann P, Põder A, Pook M, Kangur T, Kingo K, Jaks V, Mäeorg U, Järvekülg M.

Mater Sci Eng C Mater Biol Appl. 2014 Sep;42:538-45. doi: 10.1016/j.msec.2014.05.075. Epub 2014 Jun 6.

PMID:
25063151
15.

HIV in Europe.

Põder A, Haldre M.

Clin Dermatol. 2014 Mar-Apr;32(2):282-5. doi: 10.1016/j.clindermatol.2013.08.011. Review.

PMID:
24559564
16.

An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.

Poder A, Simurka P, Li P, Roy-Ghanta S, Vaughn D.

Vaccine. 2014 Feb 19;32(9):1121-9. doi: 10.1016/j.vaccine.2013.11.031. Epub 2013 Nov 16.

17.

The 2012 International Union against Sexually Transmitted Infections European Collaborative Clinical Group report on the diagnosis and management of Neisseria gonorrhoeae infections in Europe.

Brooks B, Patel R; European Collaborative Clinical Group (ECCG).

Int J STD AIDS. 2013 Jun;24(6):419-22. doi: 10.1177/0956462413476269. Epub 2013 Jul 19.

PMID:
23970741
18.

Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.

HSV-040 Study Group, Abu-Elyazeed RR, Heineman T, Dubin G, Fourneau M, Leroux-Roels I, Leroux-Roels G, Richardus JH, Ostergaard L, Diez-Domingo J, Poder A, Van Damme P, Romanowski B, Blatter M, Silfverdal SA, Berglund J, Josefsson A, Cunningham AL, Flodmark CE, Tragiannidis A, Dobson S, Olafsson J, Puig-Barbera J, Mendez M, Barton S, Bernstein D, Mares J, Ratner P.

Vaccine. 2013 Dec 9;31(51):6136-43. doi: 10.1016/j.vaccine.2013.06.081. Epub 2013 Jul 9.

PMID:
23850416
19.

AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.

McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, Durand C, Duval X, El Idrissi M, Falsey AR, Feldman G, Frey SE, Galtier F, Hwang SJ, Innis BL, Kovac M, Kremsner P, McNeil S, Nowakowski A, Richardus JH, Trofa A, Oostvogels L; Influence65 study group.

Lancet Infect Dis. 2013 Jun;13(6):485-96. doi: 10.1016/S1473-3099(13)70046-X. Epub 2013 Mar 19.

PMID:
23518156
20.

European guideline for the organization of a consultation for sexually transmitted infections, 2012.

Radcliffe KW, Flew S, Poder A, Cusini M.

Int J STD AIDS. 2012 Sep;23(9):609-12. doi: 10.1258/ijsa.2012.012115.

PMID:
23033510

Supplemental Content

Loading ...
Support Center